ArticleRadiation oncology (London, England)2019
Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality imaging.
Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Safety and Efficacy of Histotripsy Treatments Near Implanted Metallic Fiducials and Endovascular Coils in Phantoms and in an In Vivo Swine Model.Ultrasound in medicine & biology · 2026Article
- Preclinical Optimization of Magnetotactic Bacteria Therapy for the Treatment of Pancreatic and Rectal Cancer.Cancers · 2026Article
- Determination of HU override for gold fiducial markers in proton therapy.Journal of applied clinical medical physics · 2026Article
- Universal Fiducial Markers for Multi-Modal Radiotherapy.International journal of particle therapy · 2026Article
- Distance-based assessment of spatial artifact extension in the prostate from fiducial markers in diffusion-weighted magnetic resonance imaging.Journal of applied clinical medical physics · 2025Article
- Article
- Impact of bladder volume and bladder shape on radiotherapy consistency and treatment interruption in prostate cancer patients.Journal of applied clinical medical physics · 2025Article
- Interpreting Prostate Multiparametric MRI: Beyond Adenocarcinoma - Anatomical Variations, Mimickers, and Post-Intervention Changes.Seminars in ultrasound, CT, and MR · 2025Review
- Article
- Feasibility and guidelines for the use of an injectable fiducial marker (BioXmarkF1000Research · 2023Article
- Alumina as a Computed Tomography Soft Material and Tissue Fiducial Marker.Experimental mechanics · 2022Article
- A liquid immunogenic fiducial eluter for image-guided radiotherapy.Frontiers in oncology · 2022Article
- Automatic localization of the prostatic urethra for image guided radiation therapy.Technical innovations & patient support in radiation oncology · 2021Article
- A phantom study to contrast and compare polymer and gold fiducial markers in radiotherapy simulation imaging.Scientific reports · 2021Article
- Evaluation of a Novel Liquid Fiducial Marker, BioXmarkCancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn this study, a novel pelvic phantom was developed and used to assess the visibility and presence of artefacts from different types of commercial fiducial markers (FMs) on multi-modality imaging relevant to prostate cancer. METHODS AND MATERIALS: The phantom was designed with 3D printed hollow cubes in the centre. These cubes were filled with gel to mimic the prostate gland and two parallel PVC rods were used to mimic bones in the pelvic region. Each cube was filled with gelatine and three unique FMs were positioned with a clinically-relevant spatial distribution. The FMs investigated were; Gold Marker (GM) CIVCO, GM RiverPoint, GM Gold Anchor (GA) line and ball shape, and polymer marker (PM) from CIVCO. The phantom was scanned using several imaging modalities typically used to image prostate cancer patients; MRI, CT, CBCT, planar kV-pair, ExacTrac, 6MV, 2.5MV and integrated EPID imaging. The visibility of the markers and any observed artefacts in the phantom were compared to in-vivo scans of prostate cancer patients with FMs.
resultsAll GMs were visible in volumetric scans, however, they also had the most visible artefacts on CT and CBCT scans, with the magnitude of artefacts increasing with FM size. PM FMs had the least visible artefacts in volumetric scans but they were not visible on portal images and had poor visibility on lateral kV images. The smallest diameter GMs (GA) were the most difficult GMs to identify on lateral kV images.
conclusionThe choice between different FMs is also dependent on the adopted IGRT strategy. PM was found to be superior to investigated gold markers in the most commonly used modalities in the management of prostate cancer; CT, CBCT and MRI imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.